BACKGROUND: We aim to establish the normal pattern of prostate specific antigen (PSA) change with age to provide a baseline from which disease progression might be identified in prostate cancer patients included in active surveillance programs. METHODS: In a community-based study, PSA values were determined at baseline and after 2.1 and 4.2 years in men without prostate cancer. A bivariate multilevel growth curve model was used to estimate the pattern of change of PSA with age. RESULTS: The final model showed that PSA was related to age only. The future PSA of an individual can be predicted based on his age and known history of PSA. The model was also used to calculate PSA doubling time for men with different PSA values at different ages. CONCLUSIONS: This method establishes normal PSA levels by age using PSA history in men without prostate cancer. The model provides baseline data from which disease progression might be detected. (c) 2005 Wiley-Liss, Inc.
BACKGROUND: We aim to establish the normal pattern of prostate specific antigen (PSA) change with age to provide a baseline from which disease progression might be identified in prostate cancerpatients included in active surveillance programs. METHODS: In a community-based study, PSA values were determined at baseline and after 2.1 and 4.2 years in men without prostate cancer. A bivariate multilevel growth curve model was used to estimate the pattern of change of PSA with age. RESULTS: The final model showed that PSA was related to age only. The future PSA of an individual can be predicted based on his age and known history of PSA. The model was also used to calculate PSA doubling time for men with different PSA values at different ages. CONCLUSIONS: This method establishes normal PSA levels by age using PSA history in men without prostate cancer. The model provides baseline data from which disease progression might be detected. (c) 2005 Wiley-Liss, Inc.
Authors: Steven J Jacobsen; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; George G Klee; Cynthia J Girman; Michael M Lieber Journal: Mayo Clin Proc Date: 2012-01 Impact factor: 7.616
Authors: Kate Tilling; Hans Garmo; Chris Metcalfe; Lars Holmberg; Freddie C Hamdy; David E Neal; Jan Adolfsson; Richard M Martin; Michael Davis; Katja Fall; J Athene Lane; Hans-Olaf Adami; Anna Bill-Axelson; Jan-Eric Johansson; Jenny L Donovan Journal: Eur Urol Date: 2009-03-13 Impact factor: 20.096
Authors: C Metcalfe; K Tilling; M Davis; J A Lane; R M Martin; H Kynaston; P Powell; D E Neal; F Hamdy; J L Donovan Journal: Br J Cancer Date: 2009-07-14 Impact factor: 7.640
Authors: Rebecca Gilbert; Kate Tilling; Richard M Martin; J Athene Lane; Michael Davis; Freddie C Hamdy; David E Neal; Jenny L Donovan; Chris Metcalfe Journal: Cancer Causes Control Date: 2018-02-16 Impact factor: 2.506